Abstract

The emergence of biological drugs has transformed the management of severe allergic conditions, including asthma, atopic dermatitis, and eosinophilic esophagitis. Recently, the approval of omalizumab to treat multiple food allergies, in the United States, was a breakthrough in enhancing tolerance and reducing severe reactions. Dupilumab also shows promise in reducing IgE levels and symptom severity in patients with atopic dermatitis and food allergies, potentially offering a therapeutic avenue. Additionally, studies suggest dupilumab’s role in mitigating the atopic march, especially in adolescents with early-onset and severe atopic dermatitis, raising questions about the optimal window for intervention and duration of treatment. The approval of dupilumab for children aged 6 months to 5 years opens avenues for further research on preventing the atopic march from infancy

Downloads

pdf
Authors

Cristiana Indolfi - Department of Woman, Child and of General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy

Angela Klain - Department of Woman, Child and General and Specialized Surgery, University of Campania ‘Luigi Vanvitelli’, Naples, Italy

Giulio Dinardo - Department of Woman, Child and of General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy

Carolina Grella - Department of Woman, Child and of General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy

Alessandra Perrotta - Department of Woman, Child and of General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy

Fabio Decimo - Department of Woman, Child and of General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy

Michele Miraglia del Giudice - Department of Woman, Child and of General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright

Copyright (c) 2024 Italian Journal of Pediatric Allergy and Immunology

How to Cite
Indolfi, C., Klain, A., Dinardo, G., Grella, C., Perrotta, A., Decimo, F., & Miraglia del Giudice, M. (2024). The dawn of a new era for biological drugs in allergology. Italian Journal of Pediatric Allergy and Immunology, 38(3). https://doi.org/10.53151/2531-3916/2024-508
  • Abstract viewed - 119 times
  • pdf downloaded - 95 times